VivoSeq
Oncology

Rectum Cancer

66

Pipeline Programs↗

4

Active Trials↗

40

Companies Involved↗

Rectum Cancer is a moderately active landscape with 66 programs across 40 companies. The most active players are Incyte, Adlai Nortye Biopharma Co., Ltd., Synta Pharmaceuticals Corp.. 24 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

0/100

Mech. Concentration

9/100

Completion Rate

80/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

2 programs

Phase 1A

Adlai Nortye Biopharma Co., Ltd.

1 program

Phase 1S

Synta Pharmaceuticals Corp.

1 program

Phase 1Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

1 program

Phase 1E

Essen Biotech

2 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical1

Ondansetron

Novartis

Phase 18

Epacadostat

Incyte

Cyclophosphamide

Baxter Healthcare Corporation

Ganetespib

Synta Pharmaceuticals Corp.

Resveratrol

National Cancer Institute (NCI)

Mfolfirinox

Incyte

Phase 223

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Entinostat

Syndax Pharmaceuticals

Serplulimab

Shanghai Henlius Biotech

Pembrolizumab

Merck & Co.

Adebrelimab

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 310

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Envafolimab

Tracon Pharmaceuticals Inc.

Tegafur

The First Affiliated Hospital with Nanjing Medical University

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Camrelizumab

Sun Yat-sen University

Approved24

Fruquintinib

Takeda

Nitroglycerin

Viatris Specialty LLC

Regorafenib

Bayer

Indocyanine Green

CHX Technologies Inc.

Celecoxib

Philadelphia Eye Associates

Analysis

Modality Breakdown

77%

Small molecule

54 of 70 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody1420%Protein / enzyme11%Cell therapy11%

Small molecule leads; the ring shows all 70 classified programs, each share of the total. Modality classified for 100% of 70 pipeline programs.

Analysis

Trial Status

11

clinical trials

Recruiting4 · 36%
Completed4 · 36%
Unknown status2 · 18%
Terminated1 · 9%

Clinical Trials

Trial Activity

11 trials

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer
Recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT05706779·30 enrolled
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
Recruiting·UUniversity of Chicago·Phase 2·NCT06669572·35 enrolled
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT05912075·78 enrolled
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Recruiting·EEssen Biotech·Phase 1/2·NCT06530303·85 enrolled
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
Completed·TThe First People's Hospital of Changzhou·Phase 2·NCT02423226·56 enrolled
Preoperative Radiotherapy and E7046 in Rectum Cancer
Completed·AAdlai Nortye Biopharma Co., Ltd.·Phase 1·NCT03152370·29 enrolled
First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis
Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT01674309·65 enrolled
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
Completed·MMaastricht Radiation Oncology·Phase 1/2·NCT00409994·44 enrolled
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
Terminated·Eli Lilly logoEli Lilly·Phase 2·NCT00845039·4 enrolled
64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)
Unknown status·IInstitut Cancerologie de l'Ouest·Phase 2·NCT03951337·70 enrolled
Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients
Unknown status·—·Phase 2·NCT00964457·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)